Charles River Laboratories International (NYSE:CRL) Director Sells $7,901,575.00 in Stock

Charles River Laboratories International, Inc. (NYSE:CRL) Director James Foster sold 28,733 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $275.00, for a total value of $7,901,575.00. Following the completion of the transaction, the director directly owned 31,596 shares in the company, valued at $8,688,900. This trade represents a 47.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Charles River Laboratories International Stock Down 0.9%

Charles River Laboratories International stock opened at $281.78 on Friday. The firm has a market cap of $13.45 billion, a price-to-earnings ratio of -58.10, a PEG ratio of 2.95 and a beta of 1.38. The stock has a fifty day simple moving average of $222.90 and a two-hundred day simple moving average of $190.70. Charles River Laboratories International, Inc. has a 12 month low of $144.26 and a 12 month high of $288.02. The company has a current ratio of 1.35, a quick ratio of 1.04 and a debt-to-equity ratio of 0.92.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.77 by $0.25. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%.The firm had revenue of $1 billion for the quarter, compared to the consensus estimate of $980.53 million. During the same period in the prior year, the company posted $3.12 earnings per share. The company’s quarterly revenue was down 2.7% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. Equities analysts predict that Charles River Laboratories International, Inc. will post 11.35 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently issued reports on CRL shares. JPMorgan Chase & Co. raised shares of Charles River Laboratories International from a “neutral” rating to an “overweight” rating and raised their price target for the company from $180.00 to $310.00 in a report on Thursday, August 6th. Morgan Stanley increased their price objective on shares of Charles River Laboratories International from $260.00 to $300.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Barclays restated an “overweight” rating and issued a $300.00 target price on shares of Charles River Laboratories International in a report on Wednesday, August 5th. Sanford C. Bernstein set a $250.00 target price on shares of Charles River Laboratories International in a research note on Wednesday, July 1st. Finally, Piper Sandler set a $300.00 price target on Charles River Laboratories International in a report on Monday. Twelve investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $255.65.

Hedge Funds Weigh In On Charles River Laboratories International

Institutional investors have recently made changes to their positions in the business. Los Angeles Capital Management LLC bought a new stake in Charles River Laboratories International during the fourth quarter valued at approximately $42,000. Sfam LLC purchased a new position in shares of Charles River Laboratories International during the 4th quarter worth $43,000. Activest Wealth Management boosted its stake in shares of Charles River Laboratories International by 10,900.0% during the 4th quarter. Activest Wealth Management now owns 220 shares of the medical research company’s stock worth $44,000 after acquiring an additional 218 shares during the last quarter. Elyxium Wealth LLC bought a new stake in shares of Charles River Laboratories International during the 4th quarter valued at $46,000. Finally, Geneos Wealth Management Inc. grew its position in shares of Charles River Laboratories International by 98.0% during the 2nd quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock valued at $44,000 after acquiring an additional 145 shares during the period. Institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.